Sorrento Therapeutics (LTS:0L85) Days Payable: 178.89 (As of Jun. 2023)

What is Sorrento Therapeutics Days Payable?

Sorrento Therapeutics LTS:0L85 12 Days Payable is 178.89 as of Jun. 2023. GuruFocus rates LTS:0L85 with a GF Score™ of 12/100.

Sorrento Therapeutics's average Accounts Payable for the three months ended in Jun. 2023 was $16.57 Mil. Sorrento Therapeutics's Cost of Goods Sold for the three months ended in Jun. 2023 was $8.45 Mil. Hence, Sorrento Therapeutics's Days Payable for the three months ended in Jun. 2023 was 178.89.

The historical rank and industry rank for Sorrento Therapeutics's Days Payable or its related term are showing as below:

LTS:0L85's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 113.56
* Ranked among companies with meaningful Days Payable only.

Sorrento Therapeutics's Days Payable declined from Jun. 2022 (399.58) to Jun. 2023 (178.89). It may suggest that Sorrento Therapeutics accelerated paying its suppliers.

Sorrento Therapeutics Days Payable Related Terms

Sorrento Therapeutics Days Payable Historical Data

* Premium members only.

The historical data trend for Sorrento Therapeutics's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sorrento Therapeutics Days Payable Chart

Sorrento Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Days Payable

Get a 7-Day Free Trial

613.37

618.13

960.90

729.94

408.78

Sorrento Therapeutics Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Days Payable	Get a 7-Day Free Trial															399.58	349.46	285.63	546.38	178.89

LTS:0L85 vs IMUX, OCUP, KZR: Days Payable Comparison

For the Biotechnology subindustry, Sorrento Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sorrento Therapeutics Days Payable vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sorrento Therapeutics's Days Payable distribution charts can be found below:

* The bar in red indicates where Sorrento Therapeutics's Days Payable falls into.

Save Embed

12GF Score

Sorrento Therapeutics Inc LTS:0L85

Days Payable is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Sorrento Therapeutics Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Sorrento Therapeutics's Days Payable for the fiscal year that ended in Dec. 2022 is calculated as

	Days Payable (A: Dec. 2022 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2021 )	+	Accounts Payable (A: Dec. 2022 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2022 )	*	Days in Period
=	( (27.414	+	47.515)	/	2 )	/	33.452	*	365
=	37.4645					/	33.452	*	365
=	408.78

Sorrento Therapeutics's Days Payable for the quarter that ended in Jun. 2023 is calculated as:

	Days Payable (Q: Jun. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Mar. 2023 )	+	Accounts Payable (Q: Jun. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Jun. 2023 )	*	Days in Period
=	( (14.59	+	18.554)	/	2 )	/	8.453	*	365 / 4
=	16.572					/	8.453	*	365 / 4
=	178.89

Frequently Asked Questions Learn more about Days Payable →

What does a Days Payable of 178.89 mean?

Sorrento Therapeutics (LTS:0L85) has a Days Payable of 178.89 as of Jun. 2023. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Sorrento Therapeutics and its competitors.

Is Sorrento Therapeutics' Days Payable too high?

Sorrento Therapeutics' current Days Payable is 178.89. The Biotechnology industry median Days Payable is 113.56. Sorrento Therapeutics' value of 178.89 is 57.5% above this industry median. Overall, Sorrento Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.

How does Sorrento Therapeutics' Days Payable compare to IMUX and OCUP?

Sorrento Therapeutics' Days Payable of 178.89 can be compared against companies in the Biotechnology industry. The industry median Days Payable is 113.56. Sorrento Therapeutics' value of 178.89 is 57.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Days Payable for a Biotechnology company?

The median Days Payable among Biotechnology companies is 113.56, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sorrento Therapeutics's current Days Payable of 178.89 is 57.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Days Payable mean?

A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Sorrento Therapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sorrento Therapeutics's current Days Payable is 178.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Sorrento Therapeutics stock overvalued right now?

Sorrento Therapeutics (LTS:0L85) has a current Days Payable of 178.89. The current Days Payable is 178.89 and 57.5% above the Biotechnology industry median of 113.56. Sorrento Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Days Payable calculated?

Days Payable is calculated from a company's financial statements. For Sorrento Therapeutics (LTS:0L85), the current Days Payable is 178.89 as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sorrento Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies IMUX OCUP KZR HRGN CRDF SABS CDTX NGM KRON MNOV OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XKRX:068270 BNTX ALNY

Address 4955 Directors Place, San Diego, CA, USA, 92121

Website https://www.sorrentotherapeutics.com

Sorrento Therapeutics Inc is a clinical and commercial-stage biopharmaceutical company developing a portfolio of next-generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. Its multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs), and oncolytic virus (Seprehvec). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVI-AMG, COVIDROPS, COVISHIELD, FUJOVEE (Abivertinib), and OQORY (Covi-MSC), and diagnostic test solutions, including COVITRACK and COVIMARK.

12GF Score

Get the complete analysis for LTS:0L85

Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00

Price

View LTS:0L85 Analysis

See Days Payable data for all stocks →